

Toujeo® (insulin glargine 300 units/ml)

Guide for patients and/or carers

If you are prescribed Toujeo® you must be trained on how to use the Toujeo® SoloStar® pen by your healthcare professional and you must read the full instructions for use leaflet accompanying the pen. This card is provided as a guide only.

- ✓ Keep this card. You may need to read it again.

Write your name on this card: _____

- ✓ This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours

Toujeo® SoloStar® is a prefilled injection pen which contains insulin glargine 300 units per ml. It is a modified insulin, very similar to human insulin. Toujeo® lowers your blood sugar steadily over a long period of time. It is used for once daily dosing.



The dose window of the Toujeo® SoloStar® pen shows the number of units of Toujeo® to be injected.

- ✓ **Do not make any dose re-calculation and start with the dose in units written on your medical prescription**

Insulin glargine 300 units/ml (Toujeo®) and insulin glargine 100 units/ml (Lantus®) are not bioequivalent and are therefore not interchangeable without dose adjustment (this means the drugs are not the same and you must not switch between them without adjusting the dose).

The switch from one insulin therapy to another should only be done when prescribed by your healthcare provider. The dose newly recommended by your healthcare provider should always be followed.

Your blood glucose needs to be closely monitored during the switch and the initial weeks thereafter.

Please consult your healthcare provider for further information.

Before injecting Toujeo®

- ✓ Read the instructions for use that come with the package leaflet
- ✗ If you do not follow all of these instructions, you may get too much or too little insulin

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.

You can also report side effects to Sanofi by telephone on 21493022 or alternatively by email to the Medicines Authority on postlicensing.medicinesauthority@gov.mt